New shot aims to tame tough liver virus
NCT ID NCT06505928
Summary
This study is testing an experimental injection called Hepalatide (L47) to see if it can help control chronic hepatitis D, a serious liver infection. About 90 adult patients will receive either a low dose, a high dose, or delayed treatment for 48 weeks to measure how well the drug reduces the hepatitis D virus and improves liver health. The main goal is to see if the treatment safely lowers virus levels and returns a key liver enzyme to normal.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Center for Communicable Diseases
Ulaanbaatar, Mongolia
-
National cancer canter of Monglia
Ulaanbaatar, 13370, Mongolia
Conditions
Explore the condition pages connected to this study.